Just one day after CEO Stéphane Bancel’s sudden announcement of a 10% workforce reduction, Moderna has released Q2 2025 that that fell short of analyst expectations.

Moderna Inc. said it will reduce its global workforce by roughly 10% before year’s end, responding to sharply reduced demand ...

Moderna Inc. (NASDAQ:MRNA) reported on Friday a second-quarter loss of $2.13 per share, beating the consensus of a $2.98 loss ...

Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 7.1% in the afternoon session after the company trimmed the upper ...

Sources also say that the administration plans to split CBER in two, with one of the section focused entirely on vaccines.

Since taking office, President Donald Trump has brusquely removed a number of top officials from their positions, including a ...

Biotech firm aims to streamline operations and reinvest in high-growth areas such as oncology and rare diseases as it targets ...

Moderna Inc. shares declined as the company’s cost-cutting efforts failed to assuage investors who are worried about the ...

(NASDAQ:MRNA) today reported financial results and provided business updates for the second quarter of 2025. "In the last three months, we advanced our pipeline with positive Phase 3 flu vaccine ...

Moderna topped Wall Street sales expectations and reported a lower-than-expected second-quarter loss on Friday, driven by ...

The Moderna layoffs are aimed at cutting costs amid declining vaccine sales and a shifting regulatory landscape.

In a memo, CEO Stéphane Bancel said the job cuts are needed to align the struggling vaccine maker’s cost structure with the ...